Ho-sik Oh

Title: Ho-sik Oh: Innovator in Antibody Development

Introduction

Ho-sik Oh is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies for therapeutic applications. With a total of 2 patents, his work focuses on innovative solutions for cancer treatment.

Latest Patents

Ho-sik Oh's latest patents include groundbreaking advancements in antibody technology. One of his notable inventions is the "Anti-human 4-1BB antibodies and uses thereof." This patent provides anti-human 4-1BB antibodies and fragments that possess unique structural features, enhancing their effectiveness compared to reference antibodies. The methods associated with this patent include inducing T-cell proliferation and secretion of IFNγ, as well as employing these antibodies for cancer detection, prevention, and treatment.

Another significant patent is the "Monoclonal antibody which specifically recognizes B cell lymphoma and use thereof." This invention details a monoclonal antibody that targets B cell lymphoma cells. It encompasses a range of applications, including a pharmaceutical composition for preventing or treating B cell lymphoma, diagnostic methods, and the development of CAR-modified T cells for enhanced therapeutic efficacy.

Career Highlights

Ho-sik Oh is currently associated with Eutilex Co., Ltd., where he continues to advance his research in antibody development. His work has positioned him as a key figure in the biotechnology sector, contributing to innovative treatments for cancer.

Collaborations

Throughout his career, Ho-sik Oh has collaborated with notable colleagues, including Byoung S Kwon and Seoung-Joo Lee. These partnerships have fostered a collaborative environment that enhances the research and development of novel therapeutic solutions.

Conclusion

Ho-sik Oh's contributions to antibody technology represent a significant advancement in the fight against cancer. His innovative patents and ongoing research at Eutilex Co., Ltd. highlight his commitment to improving therapeutic options for patients.